Get started
Author

Amulya Uppala

Observed names: A. Uppala, Uppala Amulya
ORCID: 0000-0001-5457-9298
Observed ORCID: 0000-0001-5457-9298
OpenAlex ID: A5086200679
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma
2024 · T.M. Kim, M. Taszner, et al. · Annals of Oncology · 89
PDF
Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up
2023 · Jose. C. Villasboas, Tae Min Kim, et al. · Blood · 14
Cefazolin versus fluoroquinolones for the treatment of community-acquired urinary tract infections in hospitalized patients
2019 · Amulya Uppala, Esther A. King, et al. · European Journal of Clinical Microbiology & Infectious Diseases · 12
Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3).
2024 · Matthew Matasar, Burhan Turgut, et al. · Journal of Clinical Oncology · 10
Efficacy and Safety of Odronextamab in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Data from the R/R MZL Cohort in the ELM-2 Study
2024 · Tae Min Kim, Seok-Goo Cho, et al. · Blood · 8
Methods and Barriers to Communication Between Pharmacists During Transitions of Care
2021 · Jessica Wooster, Laressa Bethishou, et al. · Journal of Pharmacy Practice · 8
Pb2335: Trial in Progress: Phase 3 Trial Evaluating the Efficacy and Safety of Odronextamab Plus Chop (o-chop) Versus R-chop in Previously Untreated Diffuse Large B-cell Lymphoma (olympia-3)
2023 · Benoit Tessoulin, Stephanie Guidez, et al. · HemaSphere · 7
Impact of a COPD care bundle on hospital readmission rates
2022 · Moira E. Kendra, Anjali Kakwani, et al. · Journal of the American Pharmacists Association · 7
PDF
Mediating Roles of Customer Experience on E-Loyalty
2019 · Uppala Amulya · Ushus - Journal of Business Management · 4
PDF
Efficacy and safety of long-term odronextamab treatment in patients with relapsed/refractory follicular lymphoma: 3-year follow-up from the Phase 2 ELM-2 study
2025 · Jose Villasboas Bisneto, Deepa Jagadeesh, et al. · Blood · 3
Trial in Progress: Odronextamab for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Prior BTK Inhibitor Therapy - a Cohort of the ELM-2 Study
2024 · Seok-Goo Cho, Tae Min Kim, et al. · Blood · 3
Corrigendum to “Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma”
2024 · T.M. Kim, M. Taszner, et al. · Annals of Oncology · 2
Abstract CT243: Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
2024 · Geoffrey Chong, Michal Taszner, et al. · Cancer Research · 2
Pb2279: Trial in Progress: Odronextamab, a Cd20×cd3 Bispecific Antibody, for the Treatment of Patients With Relapsed/refractory Marginal Zone Lymphoma (mzl) – a Cohort From the Elm-2 Study
2023 · Seok-Goo Cho, Tae Min Kim, et al. · HemaSphere · 1
Odronextamab treatment for patients with rare subtypes of relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL): Updated efficacy and safety analyses from a dedicated cohort of the ELM-2 study
2025 · Mary-Margaret Keating, Tae Min Kim, et al. · Blood
PDF
242 | Long‐term Efficacy and Survival Outcomes With Odronextamab in Relapsed/refractory Follicular Lymphoma (r/r Fl): 2‐year Follow‐up From the Phase 2 Elm‐2 Study
2025 · S. Luminari, M. Taszner, et al. · Hematological Oncology
PDF
Trial in Progress: Odronextamab, a Cd20×cd3 Bispecific Antibody, for the Treatment of Relapsed/refractory Marginal Zone Lymphoma (r/r Mzl)—a Cohort From the Elm‐2 Study
2023 · S. Cho, T. M. Kim, et al. · Hematological Oncology
PDF
Impact of a Chronic Obstructive Pulmonary Disease Care Bundle on Hospital Readmission Rates
2020 · M. Kendra, A. Kakwani, et al.
Works count: 18
Citation count: 170
H-index: 7
I10-index: 4
Year
Topic
Type